Valuation dashboard for Incyte Corporation (INCY) with P/E 64.04, P/B 4.34, EV/EBITDA 24.25 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive a...
Analysis Summary
Incyte Corporation reported revenue of $5.14B in the most recent fiscal year, growing at a 5-year CAGR of 14.0%.
Trailing-twelve-month margins: gross margin 92.7%, operating margin 11.6%, net margin 6.7%.
At $120.39 (closing price, October 30, 2026), INCY trades at a P/E of 64.04 and an ROE of 7.11%. Market capitalisation stands at $24.5B, placing it among large-cap names.
Balance sheet quality for INCY: current ratio of 3.3. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 64.04 |
| Price / Book | 4.34 |
| EV / EBITDA | 24.25 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $109.78 |
| vs Current Price | -8.8% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| INCY | Incyte Corporation | $24.5B | 64.04 | 4.34 | 7.1% |
| REGN | Regeneron Pharmaceuticals, Inc. | $95.5B | 20.50 | 2.82 | 15.1% |
| GMAB | Genmab A/S | $35.1B | 44.96 | 6.01 | 13.6% |
| EXEL | Exelixis, Inc. | $17.4B | 20.78 | 9.34 | 45.5% |
| LGND | Ligand Pharmaceuticals Incorporated | $6.4B | 144.08 | 6.70 | 5.2% |
| LEGN | Legend Biotech Corporation | $4.0B | 3.29 | -8.7% | |
| NRIX | Nurix Therapeutics, Inc. | $2.9B | 11.60 | 3.09 | 49.3% |
Price
| Price | $120.39 (closing price, October 30, 2026) |
| Market Cap | $24.5B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | 7.11% |
| Return on Invested Capital | 6.03% |
| Return on Assets | 5.54% |
| Gross Margin | 92.69% |
| Operating Margin | 11.61% |
| Net Margin | 6.71% |
Related companies: REGN · GMAB · EXEL · LGND · LEGN · NRIX
Explore sector: Healthcare · Biotechnology
More sections of INCY: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks